Related Experiment Video
Updated: May 17, 2026

Synthesis and Characterization of 1,2-Dithiolane Modified Self-Assembling Peptides
Published on: August 20, 2018
Exposures to 1,3-dimethylamylamine-containing products reported to Texas poison centers
1Epidemiology and Disease Surveillance Unit, Texas Department of State Health Services, Austin, Texas 78756, USA. matthias.forrester@dshs.state.tx.us
Abstract:
1,3-Dimethylamylamine (DMAA) is an ingredient in a number of weight loss and exercise performance enhancing products. However, information on the safety of DMAA-containing products is limited. Exposures to DMAA-containing products reported to Texas poison centers during 2010-2011 were identified and selected factors were examined. A total of 56 exposures were found, of which 75.0% were reported during 2011. OxyElite Pro™ was the reported product in 80.4% of the exposures. The patients were 51.8% male and 55.4% age ≤5 years. The patient was managed on site (such as at home) in 57.1% of the cases, and the exposure was known or expected to result in an outcome that was classified as not serious in 80.4%. The most frequently reported clinical effects were tachycardia (28.6%), nausea (16.1%), and vomiting (12.5%). The most common treatments were dilution (41.1%), food (19.6%), and activated charcoal (14.3%). It should be noted that the adverse clinical effects may be due to other ingredients in the DMAA-containing products, such as caffeine.
Related Concept Videos
Physical Properties of Amines
Pharmaceutical Poisoning: Potential Scenarios
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Toxidromes: Clinical Features
Pharmaceutical Poisoning: Treatment Strategies
2° Amines to N-Nitrosamines: Reaction with NaNO2

